AFTER-HOURS TRADING - Breaking News...%CUSTOM_MINE
| From: | Allie Wyatt | Date: | Thu, 04 Dec 2003 13:59:25 +0000 |
| Subject: | AFTER-HOURS TRADING - Breaking News...%CUSTOM_MINE | ||
| Groups: | php.pear.webmaster | ||
| Request: | Send a blank email to pear-webmaster+get-867@lists.php.net to get a copy of this message | ||
AFTER-HOURS TRADING - BREAKING NEWS
Get Quote - http://quote.money.cnn.com/quote/quote?symbols=htds
Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin Toxicity Study and
Formation of Scientific Advisory Panel - Wednesday December 3, 8:04 pm ET
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases Incorporated (Pink Sheets:
HTDS) announces today that the spokesperson for the independent medical group conducting the testing
for HTTD (HTDS) has forwarded the formal Testing Results of Tubercin®'s Toxicity Trials to
HTTD.
Tubercin of five different concentrations was administered to five groups of mice. A pathologist at
the University of Oklahoma Health Science Center performed autopsies. The mice were randomized and
only the control mouse was known to the pathologist, as stated in the cover letter of the Pathology
Report.
The report concludes, "All tissues evaluated, visceral organs and the brain were essentially
normal in appearance." "The importance of this report is even better than I
expected," stated the spokesperson for the medical group. "As the testing continues and if
the results are similar to those of Chemotherapy and or radiation with no harmful side effects,
Tubercin has enormous potential for the treatment of cancer and the immune system."
The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a Scientific Advisory
Panel with leading Oncologists and Immunologists from prestigious institutions in the U.S. The panel
will review the reports and results of Tubercin®'s findings and will report back to Mr. King
with the ongoing reports in layman language for the shareholders.
"We are continuing to receive promising results regarding Tubercin® and we're looking
forward to additional positive results in the near future," stated Mr. King. "These tests
prove that Tubercin® is non-toxic and is the first step on the way to human clinical trials as well
as the first positive breakthrough conducted in the United States with an independent medical group
for Tubercin®.
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated ("HTTD") holds
the international marketing rights, except South Korea, to Tubercin®, a patented immunostimulant
developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties
unlike other cancer products are clearly stated in the abstract summary of the patent... "A
carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan
structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer
patients without incurring any adverse side effects."
Statements in this press release that are not historical facts are forward-looking statements within
the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding
the intent, belief or current expectations of the Company and its management. Such statements
reflect management's current views, are based on certain assumptions and involve risks and
uncertainties. Actual results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be dependent upon a
variety of factors, including, but not limited to, our ability to obtain additional financing and
access funds from our existing financing arrangements that will allow us to continue our current and
future operations and whether demand for our product and testing service in domestic and
international markets will continue to expand. The Company undertakes no obligation to publicly
update these forward-looking statements to reflect events or circumstances that occur after the date
hereof or to reflect any change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.
ococmbr
ozsrocrsuji knhoowsbi kzfuqcurwlrf
sovhyxyvdyyjglnu sgc usbx
lsy qkyzwn pgekulc